Press release
Compugen's Computational Discovery Leverages Single Cell Spatial Transcriptomics to Gain In-Depth Understanding of the Tumor Microenvironment
- Combining computational expertise with cutting-edge single cell technology Compugen showed PVRIG at the sites of T cell priming in the tumor
About this update from Compugen Ltd.
[{"type":"text","content":"- Combining computational expertise with cutting-edge single cell technology Compugen showed PVRIG at the sites of T cell priming in the tumor microenvironment\n - Preliminary findings further support the rationale for blocking PVRIG to address immunotherapy resistance in inflamed and less inflamed tumors\n - Approach provides additional armamentarium to discover novel targets and gain biological insights for development of novel immunotherapies\n - Oral presentation today at the Keystone Symposium: Cancer Immunotherapy: Decoding the Cancer Immunity Interactome\n\n\nHOLON, Israel, March 21, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), (\"Compugen,\" the \"Company\"), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will give a presentation today on exploring the immune-tumor microenvironment (TME) using high resolution single-cell spatial transcriptomics at the Keystone Symposium: Cancer Immunotherapy: Decoding the Cancer Immunity Interactome, March 20-24 at Whistler, British Columbia, Canada. \n\"Compugen's predictive computational platform is the cornerstone of our drug discovery and development capabilities. The biology of the TME is complex, and an in-depth understanding is required to develop novel cancer immunotherapies,\" said Anat Cohen-Dayag, Ph.D., President and CEO of Compugen. \"At the Keystone Symposium, we will share how we are successfully employing high resolution single cell spatial mapping of immune cells to decipher this complexity. Leveraging our long-term expertise in computational immuno-oncology biology we have used a cutting-edge technology to provide an unprecedented view into the composition and spatial localization of individual cells in the TME. Initial findings further suggest the presence of the DNAM-1 pathway including PVRIG, an immune checkpoint discovered by Compugen, at the sites of T cell priming, including the tertiary lymphoid structures. This is exciting as it confirms what we have seen previously and further supports the rationale to block PVRIG to address immunotherapy resistance in both inflamed and less inflamed tumors. Our ability to study cancer at the spatially resolved single-cell level is expanding our understanding of the complex interactions in the TME and opens the door to new therapeutic approaches.\"\nC...